首页> 外国专利> PHENYLAMINO-ACETIC ACID 1-(PYRIDIN-4-YL)-METHYLIDENE-HYDRAZIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF G PROTEIN-COUPLED RECEPTOR KINASES FOR THE TREATMENT OF EYE DISEASES

PHENYLAMINO-ACETIC ACID 1-(PYRIDIN-4-YL)-METHYLIDENE-HYDRAZIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF G PROTEIN-COUPLED RECEPTOR KINASES FOR THE TREATMENT OF EYE DISEASES

机译:苯胺基乙酸[1-(吡啶-4-基)-亚甲基]-酰肼衍生物及相关化合物作为G蛋白偶联受体激酶的调节剂,用于治疗眼病

摘要

Hydrazide compounds with GPCR desensitization inhibitory activity are provided that may be used to influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the hydrazide compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions controlled or influenced by GPCRs are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer osteoporosis and glaucoma are also provided. (Formula (I)). A is selected from a heteroaryl group (i): wherein X1, X2, X3 and X4 are, independently, CH, O, S or N-R6, with the proviso that at least one of X2 or X3 is O, S or N-R6; and a heteroaryl group (ii): wherein X5 and X9 are CH or C-halogen, X6 and X8 are CH, and X7 is N, and wherein the six-membered heteroaryl group may be further fused with an unsubstituted six-member aryl group; R1, R2, R3, R4, and R5 are, independently, hydrogen; halogen; C1-C4 alkyl; amino; nitro; cyano; heteroaryl; carboxy, carbonylamino; aminosulfonyl; sulfonylamino; aminoacyl; thioalkyl; sulfonyl; acyl; heterocycle; -OR; -O-C1-C4alkyl-heterocycle; -C(O)NH-C1-C4alkyl-heterocycle; -C(O)NH-heteroaryl; -C(O)NH-aryl; or carboxylamino; wherein R is C1-C4 alkyl; aryl, heteroaryl, C1-C4 alkyl aryl or C1-C4 alkyl heteroaryl; R6 is H or C1-C4 alkyl; R7 is hydrogen, C1-C4 alkyl or C1-C4 alkoxy; and X is N-R6.
机译:提供了具有GPCR脱敏抑制活性的酰肼化合物,其可用于影响,抑制或减少G蛋白受体激酶的作用。还提供了包括治疗有效量的酰肼化合物和药学上可接受的载体的药物组合物。还提供了使用化合物和/或组合物影响由GPCR控制或影响的疾病状态或状况的各种方法。还提供了使用化合物和/或组合物影响疾病状态或病症例如癌症骨质疏松症和青光眼的各种方法。 (式(I))。 A选自杂芳基(i):其中X 1,X 2,X 3和X 4独立地是CH,O,S或N-R 6,条件是X 2或X 3中的至少一个是O,S或N。 -R6;杂芳基(ii):其中,X 5和X 9为CH或C-卤素,X 6和X 8为CH,X 7为N,并且所述六元杂芳基可以进一步与未取代的六元芳基稠合。 ; R1,R2,R3,R4和R5独立地是氢;卤素; C1-C4烷基;氨基硝基氰基;杂芳基羧基,羰基氨基;氨基磺酰基磺酰氨基;氨基酰基硫代烷基磺酰基酰基杂环-要么; -O-C1-C4烷基-杂环; -C(O)NH-C1-C4烷基-杂环; -C(O)NH-杂芳基; -C(O)NH-芳基;或羧基氨基;其中R是C1-C4烷基;芳基,杂芳基,C 1 -C 4烷基芳基或C 1 -C 4烷基杂芳基; R6是H或C1-C4烷基; R7是氢,C1-C4烷基或C1-C4烷氧基; X是N-R6

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号